'No Future Without New Drugs': Yuhan CSO On Open Innovation Strategy
TPD, RNA, Cell/Gene Therapies All In Sights
Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.
